12/03/2014
Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Trial of Xyrem® (Sodium Oxybate) In Children And Adolescents Who Have With Cataplexy http://tinyurl.com/o6uo4zs
DUBLIN, Dec. 2, 2014 /PR Newswire UK/ -- Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Trial of Xyrem® (Sodium Oxybate) In Children And Adolescents Who Have Narcolepsy With Cataplexy.